Published in final edited form as:

Gynecol Oncol. 2016 February ; 140(2): 359–368. doi:10.1016/j.ygyno.2015.11.010.

Maintaining Sexual Health throughout Gynecologic Cancer Survivorship: A Comprehensive Review and Clinical Guide

Laura B. Huffman^a, Ellen M. Hartenbach^a, Jeanne Carter^{b,c}, Joanne K. Rash^a, and David M. Kushner^a

^aDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Wisconsin School of Medicine and Public Health, Madison WI

^bDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY

^cDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY

Abstract

Objective—The diagnosis and treatment of gynecologic cancer can cause short- and long-term negative effects on sexual health and quality of life (QoL). The aim of this article is to present a comprehensive overview of the sexual health concerns of gynecologic cancer survivors and discuss evidence-based treatment options for commonly encountered sexual health issues.

Methods—A comprehensive literature search of English language studies on sexual health in gynecologic cancer survivors and the treatment of sexual dysfunction was conducted in MEDLINE databases. Relevant data are presented in this review. Additionally, personal and institutional practices are incorporated where relevant.

Results—Sexual dysfunction is prevalent among gynecologic cancer survivors as a result of surgery, radiation, and chemotherapy--negatively impacting QoL. Many patients expect their healthcare providers to address sexual health concerns, but most have never discussed sex-related issues with their physician. Lubricants, moisturizers, and dilators are effective, simple, non-hormonal interventions that can alleviate the morbidity of vaginal atrophy, stenosis, and pain. Pelvic floor physical therapy can be an additional tool to address dyspareunia. Cognitive behavioral therapy has been shown to be beneficial to patients reporting problems with sexual interest, arousal, and orgasm.

Corresponding Author: David M. Kushner, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue Rm H4/664, Madison, WI 53792, Phone 608-262-2262, Fax 608-265-6572, DMKushner@wisc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest statement

Dr. Kushner reports that he is the current chair and Dr. Carter reports that she is the current vice-chair of the Scientific Network on Female Sexual Health and Cancer, an organization founded at the University of Chicago and now operated from the University of Wisconsin-Madison, both not-for-profit organizations. Neither Dr. Kushner nor Dr. Carter receive compensation for their roles. The other authors declare no conflicts of interest.

Conclusion—Oncology providers can make a significant impact on the QoL of gynecologic cancer survivors by addressing sexual health concerns. Simple strategies can be implemented into clinical practice to discuss and treat many sexual issues. Referral to specialized sexual health providers may be needed to address more complex problems.

Introduction

Gynecologic cancers are estimated to comprise over 94,000 new cancer cases in the U.S. in 2015. The most common site of diagnosis is uterine cancer followed by ovarian, cervical, and vulvar cancer [1]. In 2014 there were 14.5 million cancer survivors living in the U.S., 14% of which were gynecologic cancer survivors, and this number is anticipated to grow to almost 19 million by 2024 [2]. With the growing number of gynecologic cancer survivors, attention to survivorship and quality of life (QoL) is crucial to the comprehensive care of patients.

According to the World Health Organization, sexual health is a state of physical, emotional, mental, and social well-being in relation to sexuality [3]. Sexual dysfunction refers to problems during any phase of the sexual response cycle. The prevalence of sexual dysfunction in the general U. S. population is approximately 40% [4, 5], but can approach 90% in gynecologic oncology patients [6], with associated poor psychosocial adjustment and QoL [7]. Gynecologic malignancy and treatment with surgery, chemotherapy, and/or radiation directly affect the sexual and reproductive organs. Sexual morbidity affects gynecologic cancer patients immediately following treatment [8] and during long-term survivorship [9, 10].

Despite the high prevalence of sexual dysfunction in gynecologic cancer survivors, attention to sexual health issues by healthcare providers has been suboptimal. Patients feel they would benefit from more information regarding the effects of treatment on sexual health before therapy and desire counseling from a provider post-treatment to address sexual health concerns [11, 12]. Seventy-four percent of long-term gynecologic cancer survivors believed physicians should regularly ask about sexual issues, but 64% stated a physician never initiated the conversation during their care [10]. Understanding, evaluating, and treating the sexual health issues encountered during treatment and survivorship is crucial to the comprehensive care of gynecologic cancer patients.

Many survivors are older women and some clinicians believe that sexual health issues are less important to these women. Research indicates this is not true. Lindau and colleagues investigated the sexual activity, behaviors, and sex-related problems of over 3000 U. S. adults 57 to 85 years of age and found that the majority of older adults engage in intimate relationships and regard sexuality as an important part of life [5].

The following related topics are beyond the scope of this review (although also critically important): sexual health concerns related to infertility, sexuality in patients undergoing risk-reducing bilateral salpingo-oophorectomy (BSO), breast cancer survivorship, and partner-related sexual dysfunction. This article will focus on the sexual health issues faced by gynecologic cancer survivors and discuss treatment options for the most common problems.

Impact of Gynecologic Cancer on Sexual Health

Endometrial Cancer

Endometrial cancer is the most common gynecologic malignancy in Western countries, and it is estimated 54,870 new cases will occur in the United States in 2015 [13]. The majority will occur in postmenopausal women and surgery is the primary treatment for most patients. Standard surgical approach includes hysterectomy, BSO, with surgical staging with selective pelvic and para-aortic lymphadenectomy. Minimally invasive surgery has widely replaced laparotomy as the preferred surgical approach, providing improved blood loss, postoperative pain, complications, and length of hospital stay [14, 15] without compromising survival [16].

Many women with early-stage disease can be observed following surgery, but even in the absence of adjuvant therapy, patients are at risk of having sexual dysfunction. Onujiogu et al reported a prospective evaluation of the prevalence of sexual dysfunction in early-stage (I-IIIa) endometrial cancer patients 1 to 5 years from primary surgical treatment (N=72) [6]. Eighty-nine percent of participants had some form of sexual dysfunction determined by the Female Sexual Function Index (FSFI) score of <26 and pain was the most commonly affected domain. Only 18% of participants received adjuvant radiation therapy, suggesting that sexual dysfunction is prevalent among patients treated with surgery alone [6]. A prospective study by Aerts et al investigated sexual adjustment in surgically treated endometrial cancer patients compared to women who underwent a hysterectomy for benign indications and healthy controls (N=84 in all groups) [17]. There was no difference in reported sexual function in endometrial cancer patients before and after surgery. Furthermore, no difference in sexual function occurred in relation to the type of surgery (laparoscopy v. laparotomy) or the performance of lymphadenectomy. However, compared to healthy controls endometrial cancer patients reported more sexual dysfunction before and after surgery. Endometrial cancer patients had significantly more entry dyspareunia at 1 year compared to patients who had a hysterectomy for benign indications, and decreased sexual arousal, desire, and entry dyspareunia at 2 years compared to the healthy controls. Differences found between these three groups should be interpreted with caution as they were significantly different in age, menopausal status, education, and hormone replacement therapy use which could influence reported outcomes [17].

For patients with higher risk of recurrence and higher stage disease, adjuvant therapy in the form of radiotherapy and/or chemotherapy is typically recommended. The Post-Operative Radiotherapy in Endometrial Cancer (PORTEC-2) investigated the outcomes and adverse effects of vaginal brachytherapy (VBT) compared to external beam radiotherapy (EBRT) for the treatment of high-intermediate risk endometrial cancer [18]. No difference in vaginal recurrence was found between the treatment groups, but less gastrointestinal side effects were reported in patients who received VBT. Longitudinal QoL assessment at 5 years showed there were no differences in sexual function between VBT and EBRT patients. However, when compared to an age-matched control population, participants in the study reported significantly more vaginal dryness and lower sexual interest, activity, and enjoyment [19].

Several small cross-sectional studies have not shown a difference in sexual function in endometrial patients undergoing hysterectomy and VBT compared to women who received hysterectomy alone [20, 21] or compared to a healthy postmenopausal control [22]. Nonetheless, Quick et al showed that compared to before the diagnosis of cancer, the majority of patients felt their vagina was smaller and reported increased vaginal dryness, more pain with intercourse, and less interest in sex [21]. In a study by Damast et al, 81% of patients who underwent hysterectomy with adjuvant VBT reported sexual dysfunction. Participants also scored lower on all domains of the FSFI than the index population of healthy women ages 18-74, but not significantly worse than a postmenopausal control [22].

Nunns et al prospectively evaluated sexual function and vaginal morbidity of endometrial cancer patients who received adjuvant VBT (N=32) or EBRT (N=43) following surgical staging [23]. Twenty patients were sexually active prior to treatment and 13 (65%) reported changes in sexual activity due to treatment, including decreased libido and frequency of sex, and 12 (60%) reported dyspareunia. Vaginal changes following radiation included vaginal stenosis, vaginal scarring, mucosal telangiectasia, and mucosal atrophy. Vaginal stenosis was not more likely to develop with the combination of EBRT and VBT [23].

In summary, the treatment of endometrial cancer presents many challenges to sexual health for female survivors. Even patients treated with surgery alone report high rates of sexual dysfunction. Surgery and adjuvant radiation are associated with vaginal morbidity and decreased sexual interest, arousal, and satisfaction.

Cervical Cancer

The surgical treatment of early-stage cervical cancer can include cervical conization, simple hysterectomy, or radical hysterectomy with pelvic lymphadenectomy. Radical hysterectomy is associated with negative effects on sexual health and QoL [24]. Short-term sexual health consequences include orgasmic problems, vaginal shortening, dyspareunia, lymphedema, genital numbness, and sexual dissatisfaction [25]. Persistent sexual health concerns include lack of sexual interest (25%), lymphedema (19%), genital numbness (71%), and insufficient lubrication (24%) [25-27]. Compared to simple hysterectomy, radical hysterectomy patients experience lower vaginal blood flow during arousal [28]. Furthermore, radical hysterectomy patients self-reported worse sexual function across all FSFI domains compared to patients who underwent cervical conization [29]. Compared to healthy women, more patients treated with radical hysterectomy report diminished sexual function both before and after surgery [30].

Radical hysterectomy has detrimental effects on bowel and bladder function that can directly and indirectly affect sexual function. Traditional radical hysterectomy is associated with urinary retention, urinary incontinence, constipation, and urgency [27]. These complications are likely due to disruption of the hypogastric and splanchnic nerve plexuses during surgery [31]. Nerve-sparing modifications have been proposed to decrease these postoperative morbidities. Compared to traditional radical hysterectomy, nerve-sparing radical hysterectomy has shown improvements in short- and long-term bowel and bladder function, less postoperative complications, and improved sexual function [32].

Many patients with cervical cancer are diagnosed in their reproductive years. The median age of diagnosis is 49, and over 38% of patients are diagnosed under age 45 [1]. Radical trachelectomy is a safe fertility-sparing surgical option for some women with early-stage cervical cancer who have not completed childbearing [33-36]. Longitudinal comparisons in patients treated with radical trachelectomy versus radical hysterectomy showed no differences in mood, distress, sexual function, and QoL [9, 37]. Many women in both treatment groups faced depression, distress, and sexual dysfunction, although improvement over time was noted in these domains. Yet, for the majority of patients after radical trachelectomy and radical hysterectomy, FSFI scores remained below the clinical cut off score, suggesting persistent sexual dysfunction [9, 37].

Radiation therapy in the form of EBRT and VBT with or without concurrent chemotherapy (chemoradiation) plays a major role in the treatment of cervical cancer both in the primary and adjuvant setting. Radiation therapy has been associated with major vaginal toxicity including stenosis, shortening, atrophy, fibrosis, and dyspareunia [38-42]. Primary or adjuvant radiation therapy has been associated with greater sexual dysfunction and vaginal toxicity compared to surgery alone in cervical cancer patients [24, 43]. The combination of surgery and radiation is associated with more vaginal shortening compared to radiation alone [8]. A few longitudinal studies have investigated the effects of radiation on QoL, sexual function, and emotional distress [8, 39, 44, 45]. Mantenga et al reported that patients who received concomitant chemoradiation experienced deterioration in body image that did not recover to baseline and 10-15% of patients suffered from severe anxiety long-term [44]. Lymphedema and menopausal symptoms negatively impacted long-term QoL [44]. Compared to age-matched controls, cervical cancer patients treated with radiation had significantly more sexual dysfunction and vaginal morbidity including decreased libido (85%), dissatisfaction in sexual life (30%), reduced vaginal dimension (50%), dyspareunia (55%), and lack of lubrication (35%) [45]. The majority of patients with dyspareunia and lack of lubrication were distressed by their symptoms [45].

In summary, cervical cancer patients experience sexual dysfunction following radical surgery and radiation therapy. Vaginal morbidity and bladder and bowel dysfunction negatively affect sexual health following radical hysterectomy. These morbidities can be reduced with less radical, nerve-sparing surgery. Women who undergo radical trachelectomy are not immune to changes in sexual function. Radiation, either as primary therapy or following surgery, results in the highest degree of sexual dysfunction and vaginal morbidity.

Ovarian Cancer

Ovarian cancer accounts for 3% of cancers in women, but is responsible for more deaths than any other cancer of the female reproductive system [1]. The majority of patients present with advanced-stage disease. Primary treatment typically consists of a sequence of surgery and chemotherapy. Surgery involves hysterectomy, BSO, omentectomy, lymphadenectomy, and tumor debulking with the goal of optimal cytoreduction, either before or after chemotherapy. Removal of the ovaries results in hormonal alterations that can cause adverse changes in sexual health [46]. Menopausal symptoms triggered by cancer therapy can be more abrupt, prolonged, and intense [47], and if not managed can lead to diminished QoL,

function, and sexual desire [48]. Sexually active ovarian cancer patients who had their ovaries removed prior to menopause had significantly lower sexual pleasure compared to ovarian cancer patients who were postmenopausal at the time of surgery [49].

In an online survey, 57% of ovarian cancer patients in the U.S. and Canada reported that their sexual life had been negatively affected by cancer and its treatment [50]. Survivors experience decreased libido, decreased arousal, problems with orgasm, and difficulty with intercourse due to treatment related side effects [51-53]. Worsening sexual discomfort has been related to diminished physical and social well-being [51]. Compared to healthy women, ovarian cancer survivors report increased vaginal dryness, more dyspareunia, less sexual activity, and lower libido [49, 54]. Sexually active survivors are more likely to be younger, married, not actively receiving treatment, less fatigued, and report a better QoL and social functioning [49, 54].

Sexual function in ovarian cancer patients can vary depending on the types of treatment received. Bukovic et al investigated sexual function in ovarian cancer patients based on treatment modality, comparing surgery alone in early stage ovarian cancer patients (group 1), the combination of surgery and chemotherapy (group 2), and advanced inoperable or metastatic ovarian cancer patients receiving chemotherapy alone (group 3) [55]. Sexual satisfaction was decreased in all patients following treatment, but was more pronounced in groups 2 and 3. The greatest concern was pain with intercourse and most patients reported body image changes. While the majority of patients felt sexual health is important after ovarian cancer treatment, this opinion varied across the groups (74% v 65% v 47%, respectively) [55].

Germ cell tumors (GCT) of the ovary present in younger patients and treatment can have repercussions on future fertility and sexual health. The GOG investigated the long-term reproductive health and sexual function of GCT survivors treated with surgery and platinum-based chemotherapy [56]. Fifty-three percent received fertility sparing surgery, of which 87% reported resumption of menses. Survivors reported less sexual pleasure and lower sexual functioning compared to controls. Patients who did not receive fertility-sparing surgery reported more discomfort with intercourse [56].

In summary, the majority of ovarian cancer survivors face negative effects on sexual function following treatment. Poor sexual function is associated with impaired QoL. Surgically-induced menopause and chemotherapy are associated with decreased sexual satisfaction. It is crucial to note the majority of ovarian cancer patients feel sexual health is important.

Vulvar Cancer

Vulvar cancer comprises approximately 5% of gynecologic malignancies and the age of onset varies. Traditionally, vulvar cancer occurred in older women, but in recent years younger women are presenting with vulvar intraepithelial neoplasia (VIN) and vulvar cancer due to human papillomavirus infection [57, 58].

Treatment of vulvar cancer is based on the size, location, and suspicion for lymph node metastases and consists of primary surgery with or without adjuvant radiotherapy or primary

radiotherapy [59]. Surgical treatment of vulvar cancer has evolved from a radical “en bloc” resection of the vulva with bilateral groin and pelvic lymph node dissections to a triple incision technique and omission of pelvic lymphadenectomy [60, 61]. Additional improvements in surgical morbidity included radical local excision and sentinel lymph node dissection in early-stage patients without compromising survival [62, 63]. Despite changes in the surgical approach to vulvar cancer, sexual morbidity remains prevalent.

Women treated with vulvar surgery suffer detrimental effects on psychological function, sexual function, and relationships with their partners. Fear of anatomical changes related to surgery, fear of pain with intercourse, depression, worsening body image, and psychological distress have been reported in women undergoing vulvectomy for premalignant and malignant lesions [11, 64, 65]. Physical changes following surgery may include vaginal narrowing, numbness along the scar, removal of the clitoris, and change in tissue quality [64, 66, 67]. When compared to healthy controls, women undergoing vulvectomy have significantly more sexual dysfunction before and after surgery [65]. A study by Gunther et al reported that patients who were not sexually active following radical vulvectomy cited genital complications from their surgery as the reason for abstinence [68]. Age, depression, and worsening functional status are risk factors for sexual dysfunction in this population [11, 69]. More extensive vulvar excision was associated with poorer sexual function and QoL in a study by Likes et al [69], but other studies found no association with the extent of surgical resection [11, 70]. Patients who underwent laser or partial resection of the clitoris reported significantly more problems with arousal compared to vulvectomy patients in whom the clitoris was spared [65].

Inguinofemoral lymphadenectomy is a part of surgical management in certain vulvar cancer patients. Complete groin dissection is associated with infection and wound breakdown in 20-40% of patients and long-term lymphedema in approximately 30% [71]. Sentinel lymph node dissection has been shown to decrease these morbidities, but is not an appropriate alternative for all patients [63]. Lymphedema is associated with poor QoL in vulvar cancer patients [72] and has been shown to negatively impact sexual function [73]. Early detection and treatment are important as lymphedema is a chronic, progressive condition.

Radiation therapy has various roles in the treatment of vulvar cancer. In the adjuvant setting, radiation therapy can be administered to the vulva to treat positive or close surgical margins and to the groins and pelvis in the setting of positive lymph nodes to prevent recurrence and improve survival. In advanced vulvar cancer not amenable to surgical resection, definitive chemo-radiation is recommended. Research evaluating sexual health following radiation for vulvar cancer patients is scarce. In a longitudinal study by Weijmar Schultz et al, a profound reduction in the ability to induce arousal and orgasm as well as a decrease in the perception of positive genital sensation during arousal and orgasm was observed in vulvar cancer patients 6 months after surgery with or without adjuvant radiation (N=10, 4 received radiation) and did not improve during the 2 year follow up [67]. In a cross-sectional study by Hazewinkel et al, inguinal radiation negatively impacted the ability to achieve orgasm [70].

In summary, vulvar surgery negatively impacts sexual function regardless of the extent of surgical resection. Lymphedema is associated with poor QoL and sexual dysfunction. More

research is needed to investigate the effects of radiation on sexual health in vulvar cancer survivors.

Evaluation and Assessment of Sexual Health in the Gynecologic Cancer Survivor

Identification of patients suffering from sexual health issues is essential in improving QoL, distress, and sexual function. An algorithm for addressing sexual health in the gynecologic cancer survivor is shown in Figure 1. Female cancer survivors should be asked about their sexual function at regular intervals and assessment should include their sexual function before cancer, current sexual activity, and how cancer treatment has affected their sexual health and relationship with their partner. The NCCN recommends the Brief Sexual Symptom Checklist for Women as a primary screening tool (Figure 2) [74, 75]. Another option is a single-item screener for self-reporting sexual problems recently published by the Patient-Reported Outcomes Measurement Information System® (PROMIS®) group and the Scientific Network on Female Sexual Health and Cancer (Figure 2) [76]. More in depth assessment can be achieved by using the FSFI (a 19-item instrument) and the PROMIS® Sexual Function and Satisfaction measures (PROMIS® SexFS- an 81-item instrument), both of which have been validated in cancer patients [77, 78].

Assessment should also include a review of past medical, surgical, sexual, social, and cancer treatment history with inquiry of a history of pain with examinations. Attention to current medications is important to identify medications that may affect sexual function, as well as documentation of previously used strategies to address vaginal health. Relationship dynamics are key to optimal sexual function and inquiring about relationship satisfaction and partner health status, including sexual function, is necessary. Pelvic exam should include standard components of routine screening and surveillance. The external and internal genitalia should be inspected for evidence of edema, scarring, stenosis, atrophy, bowel or bladder incontinence, infection, and other potential causes of discomfort. Vulvar mapping in patients who report pain by using a Q-tip test can help localize pain [79]. Assessment of pelvic muscle function, tension, and strength can identify areas of dysfunction. Dilators can be used to assess current and desired vaginal capacity and progress over time in patients reporting dyspareunia, stenosis, shortening, vulvovaginal atrophy and pain with exams. Thorough evaluation is important in identifying the likely contributors to vulvovaginal pain and/or sexual dysfunction so that the appropriate intervention may be administered.

The demands of a gynecologic oncology clinical practice are high and conversations about sexual health can be challenging. Providers may experience personal embarrassment, feeling of insufficient knowledge about the diagnosis and treatment of sexual dysfunction, and lack of community resources [80]. By simply inquiring about vulvovaginal and sexual health, providers allow the patient an open avenue to discuss concerns and can dispel myths regarding sexuality after cancer treatment. An efficient system of inquiry, assessment, and triage of treatment and referrals can be incorporated into a busy clinical practice.

Treatment Strategies for Female Sexual Dysfunction

The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) contains updated diagnoses and criteria for female sexual dysfunction in response to changing theories about the female sexual response cycle. The DSM-5 presents 3 domains of female sexual dysfunction: female sexual interest/arousal disorder, female orgasmic disorder, and genito-pelvic pain/penetration disorder [81]. In order to meet criteria for the diagnosis of female sexual dysfunction, symptoms must be present for at least 6 months and cause clinically significant distress. Although DSM-5 diagnostic criteria of these 3 domains of female sexual dysfunction will be presented, treatment options discussed may be helpful to women with these issues who may not fully meet criteria for a disorder.

Female Sexual Interest/Arousal Disorder

To meet criteria for female sexual interest/arousal disorder a patient must report a lack of or significantly reduced sexual interest/arousal that is manifested in at least 3 of the following: reduced interest in sexual activity, reduced sexual/erotic thoughts or fantasies, reduced initiation of sexual activity and typically unreceptive to a partner's attempts to initiate, reduced sexual excitement/pleasure during sexual activity in 75-100% of sexual encounters, reduced sexual interest or arousal in response to any internal or external sexual cues, reduced genital or non-genital sensations during sexual activity in 75-100% of sexual encounters [81].

The basis of desire and arousal in women is multifactorial. From a physiologic standpoint, genital vasocongestion occurs almost immediately after erotic stimulation and this is mediated by pelvic sympathetic and parasympathetic nerves [82]. However, perceived arousal often does not correlate with genital response [83]. Desire can be negatively impacted by many psychological factors including stress, anxiety, depression, poor body-image, and sexual abuse or trauma [84]. Psychotherapy is commonly used to treat patients with desire and arousal problems, especially if they are acquired or situational. Associated psychological factors should be addressed before or concurrently with the symptoms of diminished desire and arousal. Studies reporting the treatment of female sexual interest/arousal disorder in gynecologic cancer survivors are limited. However, a study by Brotto et al evaluated the effects of a mindfulness-based cognitive behavioral therapy program on sexual function in endometrial and cervical cancer survivors who reported significant sexual desire and/or arousal concerns [85]. The results of treatment were compared to a wait-list control. Treatment was associated with improved FSFI domains of desire, arousal, lubrication, orgasm, satisfaction, and overall FSFI score. Treatment did not improve pain, but did reduce sexual distress and increase perceived genital arousal [85]. Referral to a provider who specializes in cognitive-behavioral therapy and sexual psychoeducation would likely benefit patients with sexual interest and arousal concerns. Many psychologists and health educators have expertise in counseling about sexual health matters. Certified sexual health providers are available in many communities.

In August 2015 the U. S. Food and Drug Administration approved flibanserin daily at bedtime for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [86]. Flibanserin is a postsynaptic 5-HT_{1A} agonist and 5-HT_{2A} antagonist. FDA

approval was based on 3 phase-3 randomized placebo-controlled trials that included 3548 premenopausal women with HSDD (2310 treated with flibanserin, 1238 treated with placebo) [87-89]. Compared to placebo, flibanserin daily at bedtime significantly improved the number of satisfying sexual events, sexual desire, and distress related to low desire over a 24 week treatment period. The most frequent adverse events included dizziness, somnolence, nausea and fatigue occurring in 9-12% in flibanserin-treated and 3-8% placebo-treated women. In a recent randomized placebo-controlled clinical trial investigating the efficacy of flibanserin in treating postmenopausal women with HSDD, similar efficacy and adverse events were found [90].

A few additional issues warrant consideration about flibanserin. The August 2015 FDA approval of flibanserin contained a Boxed Warning highlighting the risk of severe hypotension and syncope in patients who consume alcohol while taking flibanserin, in those who also use moderate or strong CYP3A4 inhibitors, and in those who have liver impairment. Flibanserin is contraindicated in these patients. Also, if no improvement in sexual desire or associated distress is noted after 8 weeks of treatment, flibanserin should be discontinued. It is not FDA approved for treatment of postmenopausal women and has not been studied in cancer populations. The trials conducted in premenopausal women had strict inclusion criteria, including using DSM-IV criteria for the diagnosis of HSDD and excluding women taking medications commonly prescribed to oncology patients [87-89]. The trial conducted in postmenopausal women excluded women with a “gynecologic disorder,” history of hysterectomy or oophorectomy, symptomatic vaginal atrophy, and many other minor gynecologic issues [90]. Therefore, clinicians should be cautious about generalizing these findings and using the drug for gynecologic cancer survivors. Future research and clinical experience regarding efficacy and safety of flibanserin in more medically and gynecologically complex patients will be helpful in determining its role in this setting.

Female Orgasmic Disorder

Female orgasmic disorder is defined as difficulty experiencing an orgasm and/or markedly reduced intensity of orgasmic sensations in 75-100% of occasions of sexual activity [81]. In evaluating women reporting concerns achieving orgasm, it is important to inquire about adequacy, variety, and amount of stimulation during sexual activity [91]. Low education, certain religious beliefs, and feeling guilty about sex are associated with female orgasmic disorder [92] and psychological risk factors include anxiety, depression, poor body-image, and a history of abuse [91, 93]. A combined cognitive and behavioral approach is the recommended approach to treating female orgasmic disorder [91]. Directed masturbation is a behavioral technique that involves graded genital stimulation to facilitate heightened arousal and orgasm and is conducted over multiple weekly therapy visits. Success rates can be as high as 90% and are best when coupled with cognitive-behavioral therapy [91].

Selective serotonin reuptake inhibitors (SSRI) have well-established negative effects on sexual function with 31-57% of patients reporting delay or inhibition of orgasm [94]. If problems with orgasm are experienced after initiation of an SSRI, allowing tolerance to develop will resolve orgasmic dysfunction in 30-40% of patients by 6 months [95]. Persistent symptoms can be addressed by attempting to decrease the dose or switching to a

new antidepressant. Bupropion does not have the same adverse sexual side effects as SSRIs and may improve sexual function [96]. Phosphodiesterase type 5 inhibitors may improve SSRI-induced sexual dysfunction in women, but these drugs are not FDA approved for this indication [97].

Genito-Pelvic Pain/Penetration Disorder

The diagnosis of genito-pelvic pain/penetration disorder requires persistent difficulty with any one of the following: vaginal penetration during intercourse; vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts; fear or anxiety about pain in anticipation of, during, or as a result of vaginal penetration; tension of the pelvic floor muscles during attempted vaginal penetration [81]. The treatment of gynecologic malignancy is associated with many causes of genito-pelvic pain and dyspareunia. Many of these symptoms can arise from alterations in vaginal health from surgery, radiation, and chemotherapy causing vaginal shortening, stenosis, atrophy, and dryness. Restoring lubrication and a natural pH to the vagina can help alleviate many problems, especially atrophy, dryness, and pain. Strategies to improve vaginal health and the role of dilators and pelvic floor physical therapy in the treatment of pelvic and genital pain will be discussed below.

There are many non-hormonal options for the treatment of vaginal dryness and atrophy. Vaginal moisturizers are non-hormonal products intended to be used several times a week for overall vaginal health to improve tissue quality and comfort, whereas vaginal lubricants are liquids or gels applied to the external genitalia and vaginal entrance to minimize dryness and discomfort temporarily during sexual activity [98]. Replens® is a polycarbophil based vaginal moisturizer that binds to vaginal epithelium, hydrating the underlying cells, resulting in increased vaginal epithelium maturation and reduced bacterial vaginosis in small groups of women treated for symptoms of vaginal atrophy [99, 100]. A small randomized study (N=40) comparing Replens® to vaginal estrogen showed equivalent improvement in dyspareunia and vaginal irritation. Although vaginal dryness was improved from baseline in both treatments, vaginal estrogen was superior to Replens® [101]. Another type of moisturizer is hyaluronic acid, a glycosaminoglycan that has water retention and lubricating properties. Two studies have compared hyaluronic acid products to vaginal estrogen [102, 103]. Both hyaluronic acid and vaginal estrogen improved vaginal atrophy and dryness, decreased vaginal symptoms, and decreased vaginal pH [102, 103]. Another study found suppositories with hyaluronic acid, vitamin A, and vitamin E to be effective in reducing vaginal dryness and dyspareunia [104].

Vaginal lubricants are used during sexual activity to temporarily minimize dryness, pain, irritation, and mucosal tears. There are a wide variety of products that can be located over the counter. Water- or silicone-based lubricants are recommended as they wash away with warm soap and water. Petroleum-based lubricants are not recommended because they increase the risk of vaginal infection, damage latex condoms, and can be associated with an unpleasant vaginal odor. For best results, lubricant should be applied to both partners' genitals prior to sexual activity and may need to be reapplied several times. Patients should avoid lubricants with perfumes or flavors as they can be irritants [98]. An example of patient

information explaining differences between water- and silicone-based lubricants and moisturizers as well as commercially available products is presented in Table 1.

Osphena[®] (ospemifene) is currently the only FDA-approved, non-estrogen, oral pill for moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women. It is an oral selective estrogen-receptor modulator that was shown to improve vaginal health, but needs further investigation in cancer populations [105, 106]. A small randomized, controlled, double-blind trial, also investigated topical lidocaine in the treatment of severe penetrative dyspareunia in breast cancer survivors. Results indicated that lidocaine applied to the vulvar vestibular tissue before vaginal penetration reduced sexual distress and improved comfort with penetration, but further study is warranted in gynecologic cancer patients [107].

Low dose vaginal and systemic estrogen therapy are effective in treating genitourinary effects of menopause in the general population [108, 109]. The Women's Health Initiative reported systemic hormone replacement therapy with estrogen plus progestin is associated with an increased risk of coronary heart disease, stroke, and breast cancer and the risk of treatment outweighs the benefit [110]. Other studies are conflicting on whether unopposed estrogen is associated with increased breast cancer risk [111, 112]. Hormone replacement therapy is controversial in patients with hormone-receptor positive cancer. A few retrospective studies have shown that oral estrogen therapy was not associated with increased risk of recurrence in early stage endometrial cancer patients [113, 114]. A GOG study by Barakat et al was designed to test the safety of estrogen therapy in early stage endometrial cancer patients, but closed early due to poor accrual after the Women's Health Initiative results were published and was underpowered to determine the effect of estrogen on recurrence and survival [115]. Low dose vaginal estrogen alleviates symptoms of vaginal atrophy with minimal serum estrogen elevation, and is available in creams, tablets, and rings [108]. Initiation of hormone therapy requires a discussion of risks, benefits, alternatives, and the expert opinion of the treating oncologist. Many survivors of non-hormone receptor positive cancers are acceptable candidates for hormone replacement therapy, especially if they have failed other more conservative treatment options for vaginal atrophy.

The use of vaginal dilators to prevent vaginal stenosis from pelvic radiation is often recommended to gynecologic cancer patients, but data to support its effectiveness is conflicting [116, 117] and adherence to dilator use is poor [118]. Regular sexual activity can help maintain vaginal health, but in patients who are not sexually active, dilators can be helpful in vaginal rehabilitation following treatment. Survivors who did not receive radiation therapy may also benefit from dilator use. Dilators (with or without additional vibration) used in combination with lubricants or moisturizers and pelvic floor exercises can be used in patients with dyspareunia, pain with pelvic exams, and vaginal morbidity caused by surgery and estrogen deprivation [98].

Pelvic floor muscles, especially muscle strength, play an important role in sexual function. Patients with stronger pelvic floor muscle contractions on physical exam scored higher on arousal and orgasmic domains of the FSFI compared to women with weak pelvic floor muscles [119]. Furthermore, improved patient control of pelvic floor muscles can decrease

pain encountered during intercourse. Pelvic floor physical therapy is often comprised of intravaginal trigger point and massage techniques, pelvic floor muscle strengthening and relaxation exercises, biofeedback, and vaginal dilators. The goal is to improve flexibility of the paravaginal tissue, decrease tension, improve strength, and increase blood flow to the pelvic floor muscles [120]. In a prospective study of 13 patients with vestibulodynia, Goldfinger et al found that following pelvic floor physical therapy, participants reported significant reductions in pain intensity with intercourse, improved overall sexual function, and more pain-free encounters [120].

Many treatment approaches have been presented for common sexual health concerns in gynecologic cancer survivors. Figure 1 presents a sexual health schema based on patient complexity. Gynecologic oncology providers should be able to provide care across all levels, from basic conversations about sexual health to referrals to a specialty sexual health clinic. Table 2 presents a possible model to triage common sexual health issues.

Conclusion

Gynecologic cancer survivors experience sexual morbidity as a result of the diagnosis and treatment of their cancer. Sexual health is important to women in survivorship, but is rarely discussed with providers. Oncology providers can make a significant impact in the quality of life of patients by simply asking about sexual concerns. Most oncology providers are not experts in treating sexual dysfunction, but simple tools can be incorporated in clinical practice to ensure success. Addressing vaginal health issues with moisturizers, lubricants, and/or hormonal therapy (local or systemic), as medically appropriate, can be easily addressed in a surveillance visit. Identifying professionals in the community where patients can be referred for pelvic floor physical therapy, cognitive-behavioral therapy, couples counseling, and sexual education can help patients with more complex sexual issues. Furthermore, national and international resources are available to provide evidence-based recommendations, education, and promote research in women's sexual health.

Sexual health is an under-researched area in gynecologic oncology. Future studies in gynecologic cancer patients should include patient-related outcomes, identify at-risk subgroups who may benefit from early intervention, and expand the treatment options available for sexual dysfunction.

References

1. Howlander, N., et al. SEER Cancer Statistics Review 1975-2012. National Cancer Institute; 2015.
2. Society, AC. Cancer Treatment and Survivorship Facts & Figures 2014-2015. American Cancer Society; Atlanta: 2014.
3. Research, D.o.R.H.a.. Developing sexual health programmes. W.H. Organization. , editor. WHO Press; Geneva, Switzerland: 2010.
4. Laumann EO, P.A. Rosen RC. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA. 1999; 281(6):537–544. [PubMed: 10022110]
5. Lindau ST, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007; 357(8):762–74. [PubMed: 17715410]
6. Onujiogu N, et al. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol. 2011; 123(2):356–9. [PubMed: 21855974]

7. Levin AO, et al. Sexual morbidity associated with poorer psychological adjustment among gynecological cancer survivors. *Int J Gynecol Cancer*. 2010; 20(3):461–70. [PubMed: 20375814]
8. Flay LD, Matthews JH. Effects of radiotherapy and surgery on sexual function of women treated for cervical cancer. *Int J Radiat Oncol Biol Phys*. 1995; 31(2):399–404. [PubMed: 7836095]
9. Carter J, et al. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. *Gynecol Oncol*. 2010; 119(2):358–65. [PubMed: 20817227]
10. Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. *Gynecol Oncol*. 2007; 106(2):413–8. [PubMed: 17582473]
11. Green MS, et al. Sexual dysfunction following vulvectomy. *Gynecol Oncol*. 2000; 77(1):73–7. [PubMed: 10739693]
12. Hill EK, et al. Assessing gynecologic and breast cancer survivors' sexual health care needs. *Cancer*. 2011; 117(12):2643–51. [PubMed: 21656742]
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015; 65(1):5–29. [PubMed: 25559415]
14. Boggess JF, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. *Am J Obstet Gynecol*. 2008; 199(4):360, e1–9. [PubMed: 18928974]
15. Walker JL, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. *J Clin Oncol*. 2009; 27(32):5331–6. [PubMed: 19805679]
16. Walker JL, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. *J Clin Oncol*. 2012; 30(7):695–700. [PubMed: 22291074]
17. Aerts L, et al. Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study. *J Sex Med*. 2015; 12(1):198–209. [PubMed: 25402322]
18. Nout RA, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *The Lancet*. 2010; 375:816–823.
19. Nout RA, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. *Eur J Cancer*. 2012; 48(11):1638–48. [PubMed: 22176868]
20. Becker M, et al. Quality of life and sexual functioning in endometrial cancer survivors. *Gynecol Oncol*. 2011; 121(1):169–73. [PubMed: 21159367]
21. Quick AM, et al. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma. *Int J Gynecol Cancer*. 2012; 22(4):703–8. [PubMed: 22398710]
22. Damast S, et al. Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy. *Int J Radiat Oncol Biol Phys*. 2012; 84(2):e187–93. [PubMed: 22572074]
23. Nunns D, et al. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial cancer. *International Journal of Gynecological Cancer*. 2000; 10(3):233–238. [PubMed: 11240680]
24. Greimel ER, et al. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. *Psychooncology*. 2009; 18(5):476–82. [PubMed: 18702067]
25. Jensen PT, et al. Early-stage cervical carcinoma, radical hysterectomy, and sexual function. A longitudinal study. *Cancer*. 2004; 100(1):97–106. [PubMed: 14692029]
26. Pieterse QD, et al. Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. *Int J Gynecol Cancer*. 2013; 23(9):1717–25. [PubMed: 24172106]
27. Pieterse QD, et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. *Int J Gynecol Cancer*. 2006; 16:1119–1129. [PubMed: 16803495]

28. Maas CP, et al. Objective assessment of sexual arousal in women with a history of hysterectomy. *BJOG*. 2004; 111(5):456–62. [PubMed: 15104610]
29. Song T, et al. Sexual function after surgery for early-stage cervical cancer: is there a difference in it according to the extent of surgical radicality? *J Sex Med*. 2012; 9(6):1697–704. [PubMed: 22548752]
30. Aerts L, et al. Long-term sexual functioning in women after surgical treatment of cervical cancer stages IA to IB: a prospective controlled study. *Int J Gynecol Cancer*. 2014; 24(8):1527–34. [PubMed: 25180463]
31. de Kroon CD, et al. Nerve sparing in radical surgery for early-stage cervical cancer: yes we should! *Int J Gynecol Cancer*. 2010; 20(11 Suppl 2):S39–41. [PubMed: 20975361]
32. Ceccaroni M, et al. Pelvic dysfunctions and quality of life after nerve-sparing radical hysterectomy: A multicenter comparative study. *Anticancer Research*. 2012; 32:581–588. [PubMed: 22287748]
33. Burnett AF, et al. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. *Gynecologic Oncology*. 2003; 88(3):419–423. [PubMed: 12648596]
34. Diaz JP, et al. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. *Gynecol Oncol*. 2008; 111(2):255–60. [PubMed: 18755500]
35. Shepherd JH, et al. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. *BJOG*. 2006; 113(6):719–24. [PubMed: 16709216]
36. Einstein MH, et al. Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes. *Gynecol Oncol*. 2009; 112(1):73–7. [PubMed: 18973933]
37. Froeding LP, et al. Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study. *J Sex Med*. 2014; 11(2):595–604. [PubMed: 24286464]
38. Katz A, et al. Early development of vaginal shortening during radiation therapy for endometrial or cervical cancer. *Int J Gynecol Cancer*. 2001; 11:234–35. [PubMed: 11437931]
39. Schover LR, Fife M, Gershenson D. Sexual dysfunction and treatment for early stage cervical cancer. *Cancer*. 1989; 63:204–212. [PubMed: 2910419]
40. Bergmark K, et al. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med*. 1999; 340(18):1383–89. [PubMed: 10228188]
41. Brand AH, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. *Int J Gynecol Cancer*. 2006; 16(1):288–93. [PubMed: 16445647]
42. Bruner DW, et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial cancer. *Int J Radiat Oncol Biol Phys*. 1993; 27:825–830. [PubMed: 8244811]
43. Frumovitz M, et al. Quality of life and sexual functioning in cervical cancer survivors. *J Clin Oncol*. 2005; 23(30):7428–36. [PubMed: 16234510]
44. Mantegna G, et al. Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. *BMC Cancer*. 2013; 13:127. [PubMed: 23506235]
45. Jensen PT, et al. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. *International Journal of Radiation Oncology*Biophysics*. 2003; 56(4):937–949.
46. Hughes C, et al. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. *Gynecologic Oncology*. 1991; 40:42–45. [PubMed: 1824939]
47. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. *J Clin Oncol*. 2008; 26(5):753–8. [PubMed: 18258983]
48. Krychman ML, et al. Sexual oncology: sexual health issues in women with cancer. *Oncology*. 2006; 71(1-2):18–25. [PubMed: 17347586]

49. Liavaag AH, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. *Gynecol Oncol.* 2008; 108(2):348–54. [PubMed: 17996925]
50. Stewart DE, et al. “What doesn't kill you makes you stronger”: an ovarian cancer survivor survey. *Gynecol Oncol.* 2001; 83(3):537–42. [PubMed: 11733968]
51. Wenzel LB, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. *Psychooncology.* 2002; 11(2):142–53. [PubMed: 11921330]
52. Kornblith AB, et al. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. *J Psychosoc Oncol.* 2010; 28(5):451–69. [PubMed: 20730659]
53. Stead ML, et al. Psychosexual function and impact of gynaecological cancer. *Best Pract Res Clin Obstet Gynaecol.* 2007; 21(2):309–20. [PubMed: 17196433]
54. Carmack Taylor CL, et al. Predictors of sexual functioning in ovarian cancer patients. *J Clin Oncol.* 2004; 22(5):881–9. [PubMed: 14990644]
55. Bukovi D, et al. Sexual Functioning and Body Image of Patients Treated for Ovarian Cancer. *Sexuality and Disability.* 2008; 26(2):63–73.
56. Gershenson DM, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2007; 25(19):2792–7. [PubMed: 17602084]
57. Hampl M, et al. New aspects of vulvar cancer: changes in localization and age of onset. *Gynecol Oncol.* 2008; 109(3):340–5. [PubMed: 18407339]
58. Joura E, Losch A, Haider-Angeler M. 2000 Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. *J Reprod Med.* 2000; 45:613–615. [PubMed: 10986677]
59. Stehman FB, Look KY. Carcinoma of the vulva. *Obstet Gynecol.* 2006; 107(3):719–33. [PubMed: 16507947]
60. NF H, et al. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. *Obstet Gynecol.* 1981; 58:574–79. [PubMed: 7301232]
61. Ballon SC, Lamb EJ. Separate inguinal incisions in the treatment of carcinoma of the vulva. *Surg Gynecol Obstet.* 1975; 140(1):81–4. [PubMed: 1209475]
62. FB S, et al. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: A prospective study of the Gynecologic Oncology Group. *Obstet Gynecol.* 1992; 79:490–7. [PubMed: 1553164]
63. Levenback CF, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. *J Clin Oncol.* 2012; 30(31):3786–91. [PubMed: 22753905]
64. Barlow EL, et al. Sexuality and body image following treatment for early-stage vulvar cancer: a qualitative study. *J Adv Nurs.* 2014; 70(8):1856–66. [PubMed: 24433533]
65. Aerts L, et al. Psychologic, relational, and sexual functioning in women after surgical treatment of vulvar malignancy: a prospective controlled study. *Int J Gynecol Cancer.* 2014; 24(2):372–80. [PubMed: 24407574]
66. Janda M, et al. Vulvar cancer patients' quality of life: a qualitative assessment. *Int J Gynecol Cancer.* 2004; 14:875–881. [PubMed: 15361198]
67. Weijmar Schulz W, et al. Psychosexual functioning after the treatment of cancer of the vulva. *Cancer.* 1990; 66:402–407. [PubMed: 2369721]
68. Gunther V, et al. Impact of radical operative treatment on the quality of life in women with vulvar cancer--a retrospective study. *Eur J Surg Oncol.* 2014; 40(7):875–82. [PubMed: 24746935]
69. Likes WM, et al. Correlates of sexual function following vulvar excision. *Gynecol Oncol.* 2007; 105(3):600–3. [PubMed: 17306347]
70. Hazewinkel MH, et al. Long-term sexual function in survivors of vulvar cancer: a cross-sectional study. *Gynecol Oncol.* 2012; 126(1):87–92. [PubMed: 22516660]
71. Gaarenstroom KN, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. *Int J Gynecol Cancer.* 2003; 13:522–527. [PubMed: 12911732]

72. de Melo Ferreira AP, et al. Quality of life in women with vulvar cancer submitted to surgical treatment: a comparative study. *Eur J Obstet Gynecol Reprod Biol.* 2012; 165(1):91–5. [PubMed: 22795579]
73. Forner DM, Dakhil R, Lampe B. Quality of life and sexual function after surgery in early stage vulvar cancer. *Eur J Surg Oncol.* 2015; 41(1):40–5. [PubMed: 25468750]
74. Denlinger C, et al. Survivorship: Sexual Dysfunction (Female), Version 1.2013, Clinical Guidelines in Oncology. *J Natl Cancer Inst.* 2014; 12:184–192.
75. Hatzichristou D, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med.* 2010; 7(1 Pt 2):337–48. [PubMed: 20092443]
76. Flynn KE, et al. Development and Validation of a Single-Item Screener for Self-Reporting Sexual Problems in U.S. Adults. *J Gen Intern Med.* 2015
77. Flynn KE, et al. Construct validity of the PROMIS(R) sexual function and satisfaction measures in patients with cancer. *Health Qual Life Outcomes.* 2013; 11:40. [PubMed: 23497200]
78. Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. *Cancer.* 2012; 118(18):4606–18. [PubMed: 22359250]
79. Haefner HK. Critique of new gynecologic surgical procedures: surgery for vulvar vestibulitis. *Clin Obstet Gynecol.* 2000; 43(3):689–700. [PubMed: 10949770]
80. Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and intervention. *J Clin Oncol.* 2012; 30(30):3712–9. [PubMed: 23008322]
81. Association, AP. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th Edition. American Psychiatric Publishing; Washington D.C.: 2013. p. 970
82. Basson R. Sexual Desires and Arousal Disorders in Women. *N Engl J Med.* 2006; 354(14):1497–1506. [PubMed: 16598046]
83. van Lunsen RHW, Laan E. Genital vascular responsiveness and sexual feelings in midlife women: psychophysiological, brain, and genital imaging studies. *Menopause.* 2004; 11(Supplement):741–748. [PubMed: 15543026]
84. Brotto LA, et al. Women's sexual desire and arousal disorders. *J Sex Med.* 2010; 7(1 Pt 2):586–614. [PubMed: 20092454]
85. Brotto LA, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. *Gynecol Oncol.* 2012; 125(2):320–5. [PubMed: 22293042]
86. FDA Joint Meeting of Bone. Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. NDA 022526. Advisory Committee Briefing Document. 2015
87. Derogatis LR, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. *J Sex Med.* 2012; 9(4):1074–85. [PubMed: 22248038]
88. Katz M, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. *J Sex Med.* 2013; 10(7):1807–15. [PubMed: 23672269]
89. Thorp J, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. *J Sex Med.* 2012; 9(3):793–804. [PubMed: 22239862]
90. Simon JA, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. *Menopause.* 2014; 21(6):633–40. [PubMed: 24281236]
91. Laan E, et al. Standard operating procedures for female orgasmic disorder: consensus of the International Society for Sexual Medicine. *J Sex Med.* 2013; 10(1):74–82. [PubMed: 22970851]
92. Meston CM, et al. Disorders of orgasm in women. *J Sex Med.* 2004; 1(1):66–8. [PubMed: 16422985]
93. Shifren JL, et al. Sexual Problems and Distress in United States Women: Prevalence and Correlates. *Obstet Gynecol.* 2008; 112(5):970–8. [PubMed: 18978095]

94. Montejo-Gonzalez AL, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. *J Sex Marital Ther.* 1997; 23(3):176–94. [PubMed: 9292833]
95. Haberfellner E, Rittmannsberger H. Spontaneous Remission of SSRI-induced Orgasm Delay. *Pharmacopsychiatry.* 2004; 37:127–30. [PubMed: 15179969]
96. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. *Acta Psychiatr Scand.* 2006; 114(6):384–97. [PubMed: 17087787]
97. Nurnberg H, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: A randomized controlled trial. *JAMA.* 2008; 300(4):395–404. [PubMed: 18647982]
98. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. *J Sex Med.* 2011; 8(2):549–59. [PubMed: 20722792]
99. van der Laak J, et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. *J Clin Pathol.* 2002; 55:446–451. [PubMed: 12037029]
100. Wu JP, Fielding SL, Fiscella K. The effect of polycarbophil gel (Replens) on bacterial vaginosis: a pilot study. *Eur J Obstet Gynecol Reprod Biol.* 2007; 130(1):132–6. [PubMed: 16464528]
101. Bygdeman M, Swahn M. Replens versus dioestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. *Maturitas.* 1996; 23:259–263. [PubMed: 8794418]
102. Chen J, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. *J Sex Med.* 2013; 10(6):1575–84. [PubMed: 23574713]
103. Ekin M, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. *Arch Gynecol Obstet.* 2011; 283(3):539–43. [PubMed: 20135132]
104. Constantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. *European Review for Medical and Pharmacological Sciences.* 2008; 12:411–416. [PubMed: 19146203]
105. Portman D, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. *Maturitas.* 2014; 78(2):91–8. [PubMed: 24679891]
106. Bachmann GA, Komi JO, Ospemifene Study G. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. *Menopause.* 2010; 17(3):480–6. [PubMed: 20032798]
107. Goetsch MF, Lim JY, Caughey AB. A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial. *J Clin Oncol.* 2015
108. Rahn DD, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. *Obstet Gynecol.* 2014; 124(6):1147–56. [PubMed: 25415166]
109. Suckling JA, et al. Local estrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev.* 2006; 4:CD001500. [PubMed: 17054136]
110. Rossouw JE, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results From the Women's Health Initiative Randomized Controlled Trial. *Journal of the American Medical Association.* 2002; 288(3):321–333. [PubMed: 12117397]
111. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. *Menopause.* 2005; 12(6):668–78. [PubMed: 16278609]
112. Anderson GL, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. *The Lancet Oncology.* 2012; 13(5):476–486. [PubMed: 22401913]
113. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. *Gynecol Oncol.* 1990; 36:189–91. [PubMed: 2298408]
114. Suriano KA, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. *Obstet Gynecol.* 2001; 97(4):555–60. [PubMed: 11275027]

115. Barakat RR, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2006; 24(4):587–92. [PubMed: 16446331]
116. Miles TP, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy *Cochrane Database Syst Rev*. 2014; 9:CD007291. [PubMed: 25198150]
117. Johnson N, Miles TP, Cornes P. Dilating the vagina to prevent damage from radiotherapy: systematic review of the literature. *BJOG*. 2010; 117(5):522–31. [PubMed: 20163407]
118. Friedman LC, et al. Adherence to vaginal dilation following high dose rate brachytherapy for endometrial cancer. *Int J Radiat Oncol Biol Phys*. 2011; 80(3):751–7. [PubMed: 20619551]
119. Lowenstein L, et al. Can stronger pelvic muscle floor improve sexual function? *Int Urogynecol J*. 2010; 21(5):553–6. [PubMed: 20087572]
120. Goldfinger C, et al. A prospective study of pelvic floor physical therapy: pain and psychosexual outcomes in provoked vestibulodynia. *J Sex Med*. 2009; 6(7):1955–68. [PubMed: 19453890]

Highlights

- Sexual dysfunction is a prevalent, yet under-recognized and under-treated morbidity of gynecologic cancer treatment.
- A comprehensive review of sexual problems experienced by gynecologic cancer survivors is presented.
- A practical, evidence-based approach to sexual health concerns for providers caring for patients during and after treatment is discussed.

Sex Health Schema for Gynecologic Oncology Providers

**Increasing
Patient
Complexity**

Intervention

- A- Talk about sexual health and dispel myths (Figure 2)
- B- Offer simple solutions (Tables 1 and 2)
- C- Refer to local resources in the community (Table 2)
- D- Refer to specialty sexual health clinic*

Patient complexity is subjective and based on clinical evaluation and the experience of the provider. The initial inquiry and counseling about sexual health begins at level A with each patient. Providers can then navigate through the levels sequentially to address problems as they arise.

*Examples include but are not limited to:

- Program in Integrative Sexual Medicine (PRISM) for Women and Girls with Cancer at the University of Chicago. www.uchospitals.edu/specialties/obgyn/prism.html
- Women's Integrative Sexual Health (WISH) Program at University of Wisconsin. www.uwhealth.org/cancer
- Female Sexual Medicine & Women's Health Program at Memorial Sloan Kettering Cancer Center. www.mskcc.org/cancer-care/treatments

Additional Resources:

- The Scientific Network on Female Sexual Health and Cancer. Global interdisciplinary network of clinicians, researchers and healthcare professionals working to promote sexual well-being in women and girls affected by cancer. www.cancersexnetwork.org
- International Society for the Study of Women's Sexual Health. Multidisciplinary international society focused on research and education on women's sexuality. www.isswsh.org
- The American Association of Sexuality Educators, Counselors, and Therapists. Resource for finding local sexuality educators, counselors, and therapists. www.aasect.org
- Resources for purchasing quality sexual aids, lubricants, and moisturizers www.soulsource.com www.pureromance.com www.sexualityresources.com

Figure 1.

Schema and resources for promoting sexual health in gynecologic cancer survivors based on level of patient complexity.

Options for Screening for Sexual Health Concerns

Brief Sexual Symptom Checklist for Women (BSSC-W)*

Please answer the following questions about your overall sexual function

1. Are you satisfied with your sexual function?

☐ Yes ☐ No

If No, please continue.

2. How long have you been dissatisfied with your sexual function?

- 3a. The problem(s) with your sexual function is: (mark one or more)

☐ 1 Problem with little or no interest in sex

☐ 2 Problem with decreased genital sensation (feeling)

☐ 3 Problem with decreased vaginal lubrication (dryness)

☐ 4 Problem reaching orgasm

☐ 5 Problem with pain during sex

☐ 6 Other:

- 3b. Which problem is most bothersome (circle) 1 2 3 4 5

4. Would you like to talk about it with your doctor?

☐ Yes ☐ No

Single-item Screener for Self-Reported Sexual Problems**

In the past 12 months, has there ever been a period of 3 months or more when you had any of the following problems or concerns? Check all that apply.

You wanted to feel more interest in sexual activity

You had difficulty with erections (penis getting or staying hard) – MEN ONLY

Your vagina felt too dry – WOMEN ONLY

You had pain during or after sexual activity

You had difficulty having an orgasm

You felt anxious about sexual activity

You did not enjoy sexual activity

Some other sexual problem or concern

No sexual problems or concerns

Figure 2.

Options for screening for sexual health problems in gynecologic oncology survivors.

*Reprinted with permission from Hatzichristou D, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med.* 2010;7:337-348.

**Proposed by the PROMIS® group and the Scientific Network on Female Sexual Health and Cancer. Reprinted with permission from Flynn K, Development and Validation of a Single-Item Screener for Self-Reporting Sexual Problems in U.S. Adults, *JGIM.* Online publication 18 April 2015

Table 1

Lubricants and moisturizers.

	Water-Based Lubricants To be used with sexual activity	Silicone-Based Lubricants To be used with sexual activity	Moisturizers To be used daily or 2-3 times weekly for comfort
Pros	<ul style="list-style-type: none"> • Inexpensive • Compatible with condoms • Safe to use with latex and silicone dilators/toys 	<ul style="list-style-type: none"> • Never dries out • Can be used in water • Feels lush • Compatible with latex condoms • Does not contain glycerin and may help to reduce infections 	<ul style="list-style-type: none"> • Helps moisturize vaginal lining • Makes vaginal and vulvar tissues more pliable • A single application at bedtime may give relief for several days • Can also be used to moisturize the external tissues • May improve vaginal pH
Cons	<ul style="list-style-type: none"> • Dries out more easily, may need to re-apply • May feel tacky over time • Some products may contain glycerin (may increase risk of urinary & yeast infections) 	<ul style="list-style-type: none"> • More expensive • More difficult to wash off • Incompatible with silicone or rubber • Impairs sperm motility 	<ul style="list-style-type: none"> • Some products may contain glycerin (may increase risk of urinary and yeast infections)
Brands	<ul style="list-style-type: none"> • Liquid Silk™ • Sliquid® Organics Silk • Sliquid® Oceanics • Slippery Stuff® • Yes® • Good Clean Love • Liquid Assets® • Pre-Seed® • Luvena® • Sliquid® Organics Silk 	<ul style="list-style-type: none"> • Uberlube • Pjur® Eros • Pink® • ONE® Move™ • Astroglide® Silicone 	<ul style="list-style-type: none"> • Vitamin E capsules/suppositories • HYALO GYN® • Replens® • K-Y® Liquidbeads®

A non-comprehensive list of lubricants and moisturizers.

Basic triage strategies for the most common sexual health issues in cancer patients utilized by the authors.

Table 2

DSM-5 Diagnosis	Clinical Symptom	Treatment Options
Genito-Pelvic Pain/Penetration Disorder	Vaginal dryness	Moisturizer Lubricant Hormonal therapy [*]
	Pain or vaginal narrowing	Ensure proper tissue quality, moisture, and lubrication (See Table 1) Dilator and/or Vibrator Referral to pelvic floor physical therapy Consider topical lidocaine for the vulvar vestibule (for severe dyspareunia)
Female Sexual Interest/Arousal Disorder	Physical cause	Treat any physical issue (see above) Encourage pelvic floor exercises to increase circulation and tone
	No physical cause	Referral to sex therapy or marriage counselor
	Related to underlying medical condition	Optimize medical condition Evaluate medication impact
Female Orgasmic Disorder	Difficulty or inability in achieving orgasm	Treat any physical issue (see above) Vibrator
		Referral to sex therapy Erotica or romance novels Explore other methods of sexual expression (hugs and caress)

^{*}When medically appropriate.